B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Neutral rating on ProKidney (NASDAQ:PROK) and raises the price target from $3 to $4.
May 29, 2024 | 9:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has maintained a Neutral rating on ProKidney and raised the price target from $3 to $4. This indicates a slightly positive outlook but suggests that the stock may not outperform significantly in the short term.
The raised price target from $3 to $4 suggests a positive outlook for ProKidney, but the Neutral rating indicates that the stock is not expected to outperform significantly in the short term. Investors might see this as a sign of moderate confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100